Ucb SA
Other Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ucb SA
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Ucb SA
XBRU:UCB
Other Operating Expenses
€1.2B
CAGR 3-Years
79%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Financiere de Tubize SA
XBRU:TUB
Other Operating Expenses
€600
CAGR 3-Years
-88%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ucb SA
Glance View

Market Cap
47.6B EUR
Industry
Pharmaceuticals

UCB SA, a Belgian multinational biopharmaceutical company, stands at the forefront of innovation in the medical field, committed to creating value by discovering new ways to treat severe diseases. Founded in 1928, UCB has transformed over the decades from its initial focus in chemicals to pioneering developments in advanced therapeutics targeting central nervous system disorders and immunology. Anchored by a robust research pipeline and a keen focus on rare diseases and specialty care, UCB has established a strong presence globally, reflecting its strategic pivot toward patient-centric approaches. With primary research facilities stationed in Braine-l'Alleud, Belgium, and Slough, UK, the company's scientific endeavors are bolstered by collaborations with research institutions worldwide, fostering an environment ripe for breakthrough discoveries. Financially, UCB's revenue streams are predominantly derived from its established portfolio of blockbuster drugs, such as Cimzia, Vimpat, and Keppra, which serve as critical lifelines for patients dealing with autoimmune diseases, epilepsy, and other chronic conditions. The company thrives on a dynamic business model that combines in-house scientific research with strategic partnerships and acquisitions to enhance its competitive edge. This synergy not only facilitates sustained growth in its core markets but also drives expansion into emerging ones, underscoring its global reach. By reinvesting substantial portions of its earnings into research and development, UCB ensures a steady pipeline of new products, thereby maintaining its stature in the highly competitive biopharmaceutical landscape. Through such strategic maneuvers, UCB aligns its operations with the overarching goal of delivering transformative therapies that improve the quality of life for patients around the world.

UCB Intrinsic Value
231.74 EUR
Overvaluation 7%
Intrinsic Value
Price

See Also

What is Ucb SA's Other Operating Expenses?
Other Operating Expenses
1.2B EUR

Based on the financial report for Jun 30, 2025, Ucb SA's Other Operating Expenses amounts to 1.2B EUR.

What is Ucb SA's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
74%

Over the last year, the Other Operating Expenses growth was 155%. The average annual Other Operating Expenses growth rates for Ucb SA have been 79% over the past three years , 74% over the past five years .

Back to Top